SOURCE: IDenta Corp.

December 19, 2007 11:25 ET

International Drug & Explosives Detection Company IDenta Receives Patent for New Ecstasy Drug Detector -- Additional Product Patents Being Processed

HEATHROW, FL--(Marketwire - December 19, 2007) - IDenta Corp. (PINKSHEETS: IDTA) announced today that it has recently been awarded a new patent from the U.S. Patent and Trademark Office. The patent is for the development of IDenta's new Ecstasy Drug Detection Kit, which is currently being produced in Israel and marketed in a number of countries throughout the world.

The IDenta's Ecstasy Kit is the only reliable kit on the market with no false positives.

"Process patents such as this one have great value to both our company's credibility and to the market value of IDenta Corp.," explained Yaacov Shoham, IDTA CEO. "We are proud that IDenta's products can be identified in the marketplace as unique and worthy of patent status. This new patent will definitely increase the asset value of IDTA's balance sheet, thereby directly enhancing shareholder value."

The IDenta Ecstasy Drug Detection Kit patent number is 10/499,719 and is designated for "A method for the detection of compounds comprising Methylenedioxyphenyl and a testing kit for the same."

"Beginning in early 2008, we will be releasing a number of crucial announcements concerning this past year's activities and our goals for 2008," Shoham continued. "We have applied for patents for our new GHB Drug Detector and for our TATP explosive detectors, will be releasing more information about our new lead detector marketing program, and will discuss the great progress we've had this year with our U.S. marketing partner, Accutest-Jant Pharmacal."

ABOUT IDENTA

IDenta Corp. has rapidly become recognized as a worldwide leader in the development of a variety of substance detection kits including proprietary on-site drug detection kits, and explosive detection kits. IDenta develops, manufactures and distributes products for the both professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's entire product line may be found at www.identa.biz.

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact Information

  • Contact:

    For Investor Relations, lobbying interests or information concerning
    IDenta's products internationally contact:
    Yaacov Shoham
    IDenta Corp.
    CEO
    Tel: +972-52-6554487
    +972-8-9716874
    Fax: +972-8-9716875
    fpi@drugsdetector.com

    For Investor Relations in the United States contact:
    Randy Jacobs
    US Corporate Spokesman
    IDentaNews@sitcomllc.com
    1-800-316-9437

    For more information about IDenta's product line in the United States
    please contact:
    Mr. Eyal Golan
    COO
    JANT PHARMACAL CORPORATION
    16255 Ventura Blvd. #505
    Encino, CA 91436
    Toll Free: 800-676-5565
    www.accutest.net